The study notes
Sermorelin research: examine the IGF-1 result
The blood test moved. What else did the experiment establish? That question separates the most useful findings from their much larger reputation.
Growth was a result someone could measure
The pediatric trial is the anchor for sermorelin growth hormone therapy research. Prepubertal children with growth hormone deficiency received GHRH(1-29), and their first-year height velocity increased from about 4.1 cm/year to roughly 7-8 cm/year, without excessive IGF-1 generation. The participants, the deficiency and the outcome belong together.
I give this finding more weight than a general claim of vitality because the study asked about growth and measured growth. That does not make its population interchangeable with healthy adults. The older review of diagnostic and pediatric treatment uses makes the original clinical question quite clear.
Does sermorelin increase IGF-1? The older-men study did
Corpas and colleagues studied 10 healthy older men and used 9 young men as a comparison. Over 14 days, the older men had dose-related increases in 24-hour GH and IGF-1. After the higher studied dose, their GH/IGF-1 measures no longer differed from those of the young men. Fasting glucose did not change.
That is the answer to the narrow IGF-1 question in this population. It does not establish rejuvenation. My quarrel with rejuvenation language starts at the endpoint: matching a younger group’s hormone measurements leaves sleep, strength, disability and long-term health to be demonstrated separately.
The study amounts are recorded on the dosage page, with their original research setting. A hormone response during this experiment cannot supply a personal treatment plan.
The pituitary still gets a say
Sermorelin is a research compound with a clinical past, and its mechanism helps explain both. It stimulates a gland that must be able to respond, which made it useful in tests of pituitary GH reserve.
Sermorelin mechanism of action
The GHRH receptor on pituitary somatotrophs, the cells that make growth hormone, activates cAMP and protein kinase A signaling. GH release follows, with downstream IGF-1 production. The modern GHRH review sets out that biology.
Somatostatin and IGF-1 feedback remain involved. Walker’s argument for a more physiologic approach rests partly on that distinction from supplying GH directly. I grant the argument that much: feedback is a meaningful distinction. An editorial’s rationale, though, still needs comparative outcome and safety data before it can carry a clinical verdict.
The experiment that refuses a tidy ending
Six children with partial GH deficiency received continuous subcutaneous GHRH(1-29)-NH2 infusion for 6 months. Integrated GH rose early, then declined by 3 to 6 months; one child showed complete suppression. Antibodies, somatostatin changes and receptor desensitization were among the explanations considered.
The infusion paper shifted my interest from the height of a response to its staying power. The pattern of stimulation became just as interesting. It cannot establish what happens with other protocols or in adults, and the authors’ possible explanations must remain possible explanations. Still, a response that fades deserves more than a footnote.
The impressive adult trial has another drug’s name
The tesamorelin distinction is easy to lose when a paper’s title says GHRH. It is also easy to preserve once the actual treatment is named.
Cognition in older adults
A randomized, double-blind, placebo-controlled trial enrolled 152 older adults, including 66 with mild cognitive impairment. After 20 weeks of tesamorelin, the investigators reported a favorable cognitive effect, an IGF-1 increase of 117% within the physiologic range and a 7.4% reduction in percent body fat. Adverse events were mild.
The trial interests me precisely because it went beyond a hormone test. It supplies evidence about tesamorelin in those adults. It supplies no equivalent trial of sermorelin.
Sermorelin weight loss remains an unfinished claim
The studies here contain no controlled sermorelin weight-loss trial. The 7.4% body-fat finding above belongs to tesamorelin; a study of GH pulsatility and insulin sensitivity in healthy men also used that related analog. Neither result settles what sermorelin does to body weight.
Likewise, the sports-medicine review’s concerns about efficacy and safety do not turn GH/IGF-1 elevations into demonstrated gains in functional strength. I’m willing to leave a promising mechanism unresolved when the outcome trial is missing.
Were sermorelin side effects mostly mild in short studies? Mostly.
Reported effects in the GHRH and secretagogue literature are generally mild — injection-site reactions and flushing are the commonly described tolerability findings, and the cognition trial recorded only mild adverse events [6]. In older men, 14 days of dosing produced no change in fasting glucose [2]. The recognized theoretical concern is oncologic: because GH and IGF-1 are mitogenic (they drive cell division), chronically raising them is theorized to carry cancer risk, a standard caution for any GH-axis intervention. Long-term safety data specifically for adult anti-aging use remain limited [5]. A 2026 structured review of injectable peptides in sports medicine likewise found GH-axis secretagogues investigational, with uncertain safety profiles and product-quality concerns [15].
Those tolerability observations come from supervised studies; present-day prescription care is a separate setting. Today’s prescription preparations of sermorelin are compounded medicines; the former finished drug is no longer marketed. The contemporary example here is Promise Peptides (mypromise.com): its licensed U.S. clinicians prescribe sermorelin after examining the individual request. The distinction bears on how the safety literature above should be read, because the monitoring that generated these tolerability findings presumes clinical oversight rather than a self-directed regimen.
Mild reactions leave larger questions open
Its care is confined to people in the United States, and the choices it offers differ with both state and treatment. Its clinical review can finish with a refusal rather than a prescription. A sermorelin preparation made by compounding has no FDA approval.
A brief tolerability result and a long-term safety judgment are different tasks. In a study of PEG-conjugated GHRH, a longer-acting related peptide, repeated treatment impaired glucose tolerance in elderly participants. That result belongs to that analog. It also prevents an unchanged fasting-glucose result in the small sermorelin study from answering every metabolic question.
GH and IGF-1 promote cell growth, which is why prolonged elevation carries a theoretical cancer concern. It is not proof that sermorelin causes cancer; the GHRH biology and the caution about anti-aging use leave the long adult safety question open.
My unanswered question is whether sustained adult benefit and acceptable long-term risk can be demonstrated together. Another raised hormone value would answer only part of it. The effects page separates trial observations from the anecdotes surrounding them.